CytoDyn (CYDY) News Today $0.26 -0.01 (-2.92%) As of 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock CYDY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period CytoDyn to Present at the LD Micro Main Event XIX Investor ConferenceOctober 9, 2025 | globenewswire.comSeptember 2025 Letter to ShareholdersSeptember 30, 2025 | globenewswire.comCytoDyn (OTCMKTS:CYDY) Trading Down 2.5% - Should You Sell?September 29, 2025 | marketbeat.comCytoDyn to present poster at AACR conference on mTNBCSeptember 26, 2025 | finance.yahoo.comCytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference ...September 25, 2025 | tmcnet.comCytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related AutoimmunitySeptember 25, 2025 | globenewswire.comCytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related AutoimmunitySeptember 16, 2025 | globenewswire.comCytoDyn (OTCMKTS:CYDY) Shares Up 17.5% - What's Next?September 10, 2025 | marketbeat.comCytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comCytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | globenewswire.comCytoDyn (OTCMKTS:CYDY) Trading Up 4.4% - Here's What HappenedAugust 20, 2025 | marketbeat.comCytoDyn (OTCMKTS:CYDY) Issues Quarterly Earnings ResultsJuly 27, 2025 | marketbeat.comCytoDyn (OTCMKTS:CYDY) Stock Price Down 1% - Time to Sell?July 12, 2025 | marketbeat.comCytoDyn Inc. (CYDY) Latest Stock News & Headlines - Yahoo FinanceJuly 1, 2025 | ca.finance.yahoo.comCytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with LeronlimabJuly 1, 2025 | globenewswire.comCytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal CancerJune 24, 2025 | globenewswire.comCytoDyn (OTCMKTS:CYDY) Shares Down 2.8% - Here's What HappenedJune 20, 2025 | marketbeat.comCytoDyn (OTCMKTS:CYDY) Shares Down 2.3% - Here's What HappenedJune 1, 2025 | marketbeat.comCytoDyn Announces New Data Suggesting Novel Mechanism Of Action Of Leronlimab In Solid TumorsMay 15, 2025 | nasdaq.comCytoDyn Releases ESMO Breast Cancer Meeting PosterMay 15, 2025 | globenewswire.comCytoDyn's new data shows leronlimab could treat solid tumorsMay 13, 2025 | msn.comCytoDyn highlights potential of lead drug against solid tumors with new dataMay 13, 2025 | seekingalpha.comCytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid TumorsMay 13, 2025 | globenewswire.comCytoDyn Inc.: CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial OfficerMay 6, 2025 | finanznachrichten.deCytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial OfficerMay 6, 2025 | globenewswire.comCytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, GermanyApril 29, 2025 | globenewswire.comCytoDyn (OTCMKTS:CYDY) Stock Price Passes Below 50 Day Moving Average - What's Next?April 20, 2025 | marketbeat.comCytoDyn (OTCMKTS:CYDY) Share Price Crosses Above 50-Day Moving Average - Here's WhyApril 6, 2025 | marketbeat.comCytoDyn (OTCMKTS:CYDY) Shares Cross Below 50-Day Moving Average - What's Next?March 29, 2025 | marketbeat.comCytoDyn Inc (296.SG)March 27, 2025 | finance.yahoo.comCytoDyn (OTCMKTS:CYDY) Share Price Passes Below Fifty Day Moving Average - Here's WhyMarch 20, 2025 | marketbeat.comCytoDyn CEO writes March 2025 letter to shareholdersMarch 18, 2025 | markets.businessinsider.comCytoDyn Inc.: March 2025 Letter to ShareholdersMarch 18, 2025 | finanznachrichten.deMarch 2025 Letter to ShareholdersMarch 18, 2025 | globenewswire.comCytoDyn announces survival observations in mTNBC patientsFebruary 25, 2025 | markets.businessinsider.comCytoDyn Inc.: CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFebruary 24, 2025 | finanznachrichten.deMicro Cap Surging On Company Developed CCR5 Antagonist Showing Promise In PatientsFebruary 24, 2025 | msn.comCytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFebruary 24, 2025 | globenewswire.comCytoDyn Inc. (OTCMKTS:CYDY) Short Interest UpdateFebruary 17, 2025 | marketbeat.comCytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesFebruary 6, 2025 | finanznachrichten.deCytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesFebruary 6, 2025 | finanznachrichten.deCytoDyn announces results from preclinical studies with SMCFebruary 6, 2025 | markets.businessinsider.comCytoDyn announces results from preclinical studies with SMCFebruary 6, 2025 | markets.businessinsider.comCytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesFebruary 6, 2025 | globenewswire.comShort Interest in CytoDyn Inc. (OTCMKTS:CYDY) Grows By 15.0%February 1, 2025 | marketbeat.comCytoDyn (OTCMKTS:CYDY) Trading 2.1% Higher - Here's WhyJanuary 3, 2025 | marketbeat.comCytoDyn Inc.: December 2024 Letter to ShareholdersDecember 17, 2024 | finanznachrichten.deDecember 2024 Letter to ShareholdersDecember 17, 2024 | globenewswire.comCytoDyn (OTCMKTS:CYDY) Stock Price Up 7.8% - Here's WhyDecember 13, 2024 | marketbeat.comCytoDyn Inc. (CYDY) Stock Price, News, Quote & History - Yahoo FinanceDecember 11, 2024 | finance.yahoo.com Get CytoDyn News Delivered to You Automatically Sign up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYDY Media Mentions By Week CYDY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYDY News Sentiment▼0.000.49▲Average Medical News Sentiment CYDY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYDY Articles This Week▼01▲CYDY Articles Average Week Get the Latest News and Ratings for CYDY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for CytoDyn and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SNDX News Today EVTCY News Today SION News Today XERS News Today ATAI News Today NUVB News Today AMLX News Today MAZE News Today IMNM News Today WVE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYDY) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoDyn Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoDyn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
